• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
[Analysis of medication characteristics of traditional Chinese medicine in treating COVID-19 based on data mining].基于数据挖掘的中医治疗新型冠状病毒肺炎用药特点分析
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020 May 25;49(2):260-269. doi: 10.3785/j.issn.1008-9292.2020.03.14.
2
[Study on medication laws of traditional Chinese medicine of 48 patients with coronavirus disease 2019 in intensive care unit based on data mining].基于数据挖掘的48例新型冠状病毒肺炎重症监护病房患者中医用药规律研究
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2021 Oct;33(10):1175-1180. doi: 10.3760/cma.j.cn121430-20210826-01285.
3
[Study on medication regularity of traditional Chinese medicine in treatment of COVID-19 based on data mining].基于数据挖掘的中医治疗新型冠状病毒肺炎用药规律研究
Zhongguo Zhong Yao Za Zhi. 2020 Mar;45(6):1248-1252. doi: 10.19540/j.cnki.cjcmm.20200220.502.
4
Traditional Chinese medicine to treat COVID-19: the importance of evidence-based research.中医治疗新型冠状病毒肺炎：循证研究的重要性。
Drug Discov Ther. 2020;14(3):149-150. doi: 10.5582/ddt.2020.03054.
5
[Analysis of property and efficacy of traditional Chinese medicine in staging revention and treatment of coronavirus disease 2019].[中医药在新型冠状病毒肺炎分期防治中的特性与疗效分析]
Zhongguo Zhong Yao Za Zhi. 2020 Mar;45(6):1253-1258. doi: 10.19540/j.cnki.cjcmm.20200225.501.
6
[Study on screening potential traditional Chinese medicines against 2019-nCoV based on Mpro and PLP].基于Mpro和PLP筛选抗2019新型冠状病毒潜在中药的研究
Zhongguo Zhong Yao Za Zhi. 2020 Mar;45(6):1219-1224. doi: 10.19540/j.cnki.cjcmm.20200216.401.
7
[Treatment strategy and thought on classical herbal formulae for coronavirus disease 2019].[2019冠状病毒病经典方剂治疗策略与思路]
Zhongguo Zhong Yao Za Zhi. 2021 Jan;46(2):494-503. doi: 10.19540/j.cnki.cjcmm.20200603.501.
8
[Analysis of potential role of Chinese classic prescriptions in treatment of COVID-19 based on TCMATCOV platform].基于中医抗击新冠肺炎平台分析中药经典方剂在治疗新型冠状病毒肺炎中的潜在作用
Zhongguo Zhong Yao Za Zhi. 2020 Jul;45(13):3028-3034. doi: 10.19540/j.cnki.cjcmm.20200405.401.
9
[Analysis on clinical study protocols of traditional Chinese medicine for coronavirus disease 2019].[2019年冠状病毒病的中医临床研究方案分析]
Zhongguo Zhong Yao Za Zhi. 2020 Mar;45(6):1232-1241. doi: 10.19540/j.cnki.cjcmm.20200220.501.
10
[Analysis of medication regularity and pharmacodynamic characteristics of traditional Chinese medicine treatment in 444 severe cases of COVID-19].444例新冠肺炎重症病例中医治疗用药规律及药效学特征分析
Zhongguo Zhong Yao Za Zhi. 2020 Jul;45(13):3007-3012. doi: 10.19540/j.cnki.cjcmm.20200427.501.

引用本文的文献

1
Ephedrae Herba: A Review of Its Phytochemistry, Pharmacology, Clinical Application, and Alkaloid Toxicity.麻黄：本草考证、化学成分、药理作用、临床应用及生物碱毒性研究进展。
Molecules. 2023 Jan 9;28(2):663. doi: 10.3390/molecules28020663.
2
Research Progress in Chinese Herbal Medicines for Treatment of Sepsis: Pharmacological Action, Phytochemistry, and Pharmacokinetics.中药治疗脓毒症的研究进展：药理作用、化学成分和药代动力学。
Int J Mol Sci. 2021 Oct 14;22(20):11078. doi: 10.3390/ijms222011078.
3
Application of Big Data and Artificial Intelligence in COVID-19 Prevention, Diagnosis, Treatment and Management Decisions in China.大数据和人工智能在中国 COVID-19 预防、诊断、治疗和管理决策中的应用。
J Med Syst. 2021 Jul 24;45(9):84. doi: 10.1007/s10916-021-01757-0.
4
The Therapeutic Effect of Traditional Chinese Medicine on Inflammatory Diseases Caused by Virus, Especially on Those Caused by COVID-19.中药对病毒引起的炎症性疾病的治疗作用，尤其是对由新型冠状病毒肺炎引起的炎症性疾病的治疗作用。
Front Pharmacol. 2021 May 26;12:650425. doi: 10.3389/fphar.2021.650425. eCollection 2021.
5
Paeoniflorin and Hydroxysafflor Yellow A in Xuebijing Injection Attenuate Sepsis-Induced Cardiac Dysfunction and Inhibit Proinflammatory Cytokine Production.血必净注射液中的芍药苷和羟基红花黄色素A减轻脓毒症诱导的心脏功能障碍并抑制促炎细胞因子的产生。
Front Pharmacol. 2021 Apr 13;11:614024. doi: 10.3389/fphar.2020.614024. eCollection 2020.
6
Research progress of traditional Chinese medicine against COVID-19.中医药防治新冠肺炎研究进展。
Biomed Pharmacother. 2021 May;137:111310. doi: 10.1016/j.biopha.2021.111310. Epub 2021 Feb 3.
7
Licochalcone A improves the cognitive ability of mice by regulating T- and B-cell proliferation.甘草查尔酮 A 通过调节 T 细胞和 B 细胞增殖来改善小鼠的认知能力。
Aging (Albany NY). 2021 Mar 10;13(6):8895-8915. doi: 10.18632/aging.202704.
8
COVID-19: Immunology, Immunopathogenesis and Potential Therapies.新型冠状病毒肺炎：免疫学、免疫发病机制及潜在疗法
Int Rev Immunol. 2022;41(2):171-206. doi: 10.1080/08830185.2021.1883600. Epub 2021 Feb 27.
9
The efficacy and safety of Lianhua Qingwen (LHQW) for coronavirus disease 2019 (COVID-19): A protocol for systematic review and meta analysis.连花清瘟（LHQW）治疗冠状病毒病2019（COVID-19）的疗效和安全性：系统评价与荟萃分析方案
Medicine (Baltimore). 2020 Jul 24;99(30):e20979. doi: 10.1097/MD.0000000000020979.

基于数据挖掘的中医治疗新型冠状病毒肺炎用药特点分析

[Analysis of medication characteristics of traditional Chinese medicine in treating COVID-19 based on data mining].

作者信息

Fan Tiantian, Chen Yongcan, Bai Yu, Ma Fengqi, Wang Hengcang, Yang Yiping, Chen Jinxu, Lin Yuqi

机构信息

College of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China.

Tongde Hospital of Zhejiang Province, Hangzhou 310007, China.

出版信息

Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020 May 25;49(2):260-269. doi: 10.3785/j.issn.1008-9292.2020.03.14.

DOI:10.3785/j.issn.1008-9292.2020.03.14
PMID:32391675
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8800748/
Abstract

OBJECTIVE

To analysis the medication characteristics of the prescriptions issued via open channel by the National and Provincial Health Committee and the State Administration of Traditional Chinese Medicine in treating coronavirus disease 2019 (COVID-19).

METHODS

We collected the data of traditional Chinese medicine related to treatment plans published by the National and Provincial Health Committee and the State Administration of Traditional Chinese Medicine from the start of COVID-19 outbreak to February 19, 2020. The frequency analysis, cluster analysis and association analysis were performed.

RESULTS

The study collected 4 national and 34 regional prevention and treatment plans, 578 items, 84 traditional Chinese formulations, 60 Chinese patent medicines, and 230 Chinese herbs. The high frequently used herbs were , and . The commonly used traditional formulations included decoction, powder, and decoction. The Chinese patent drugs included pill, injection, and capsule. The most common paired medications were and and Two core combinations and one novel formula were discovered in the study.

CONCLUSIONS

powder and decoction are the basic formulations for syndrome of COVID-19. In addition, decoction, powder, decoction and decoction are the basic formulations for syndrome of COVID-19. The main medication characteristics are clearing heat, entilating lung, removing toxicity and removing turbidity. It shows that removing toxicity and eliminating evil are the prescription thought in treating epidemic disease of traditional Chinese medicine.

摘要

目的

分析国家和省级卫生健康委以及国家中医药管理局通过公开渠道发布的治疗新型冠状病毒肺炎（COVID-19）处方的用药特点。

方法

收集自COVID-19疫情暴发至2020年2月19日国家和省级卫生健康委以及国家中医药管理局发布的与治疗方案相关的中医药数据，进行频次分析、聚类分析和关联分析。

结果

本研究收集了4个国家级和34个地区级防治方案，共578项，84个中药方剂，60种中成药，230味中药。高频使用的中药有 、 和 。常用的中药方剂有 汤、 散和 汤。中成药有 丸、 注射液和 胶囊。研究发现最常见的配对药物是 与 以及 ，还发现了两个核心组合和一个新方剂。

结论

散和 汤是COVID-19 证的基本方剂。此外， 汤、 散、 汤和 汤是COVID-19 证的基本方剂。主要用药特点为清热、宣肺、解毒、化浊。表明解毒祛邪是中医治疗疫病的处方思路。

需注意，原文中部分草药名称缺失，翻译时用“ ”代替了。